Processing of equine bone marrow using the automated MarrowXpress System: RBC depletion, volume reduction, and mononuclear cell recovery

Sean D Owens, Julie Burges, Jennifer L. Johns, Danielle D. Carrade, Larry D Galuppo, Fred Librach, Dori L Borjesson

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Background: The therapeutic use of bone marrow-derived mononuclear cells (MNCs) and mesenchymal stem cells for the treatment of soft tissue and orthopedic injuries in equine patients is expanding. After collection, bone marrow must be reduced in volume and depleted of RBCs for immediate therapeutic use or to prepare cells for culture or cryopreservation and storage. The MarrowXpress (MXP) System is an automated, closed, sterile system designed to process human bone marrow samples. Objectives: The purpose of this study was to evaluate the capacity of the MXP System to process equine bone marrow to reduce volume, deplete RBCs, and enhance recovery of MNCs. Methods: Bone marrow was collected from 47 horses into 2 60-mL syringes containing heparin and processed using the MXP System. HCT, total nucleated cell (TNC) count, and MNC count were obtained for each sample before and after processing using an Advia 120 hematology analyzer. Volume reduction, RBC depletion, and recovery of TNCs and MNCs were calculated. Results: For equine bone marrow samples, mean values were 73.2% for RBC depletion and 78.0% for volume reduction. TNC count before processing was 2.5 ± 1.2 × 107 and after processing was significantly higher at 7.8 ± 3.3 × 107 (P < .0001), with a recovery of 68.5 ± 24.5% (mean ± SD). MNC count before processing was 1.1 ± 0.9 × 107 and after processing was significantly higher at 3.8 ± 1.9 × 107 (P < .0001), with a recovery 73.0 ± 31.5%. Conclusions: The MXP System can reliably reduce volume and deplete RBCs from aspirates of equine bone marrow aspirates. MNCs can be recovered in a reproducible and sterile manner. Further studies evaluating the effects of the MXP System on cell viability, identification of mesenchymal stem cells (MSCs), and the efficacy of MSC expansion are warranted.

Original languageEnglish (US)
Pages (from-to)444-449
Number of pages6
JournalVeterinary Clinical Pathology
Volume40
Issue number4
DOIs
StatePublished - Dec 2011

Fingerprint

bone marrow
Horses
erythrocytes
Bone Marrow
horses
Cell Count
Mesenchymal Stromal Cells
cells
stem cells
Therapeutic Uses
Soft Tissue Injuries
Cryopreservation
Syringes
therapeutics
Hematology
syringes
orthopedics
heparin
hematology
Orthopedics

Keywords

  • Cartilage
  • Cell separation
  • Horse
  • Mesenchymal stem cells
  • Musculoskeletal
  • Tendon

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Processing of equine bone marrow using the automated MarrowXpress System : RBC depletion, volume reduction, and mononuclear cell recovery. / Owens, Sean D; Burges, Julie; Johns, Jennifer L.; Carrade, Danielle D.; Galuppo, Larry D; Librach, Fred; Borjesson, Dori L.

In: Veterinary Clinical Pathology, Vol. 40, No. 4, 12.2011, p. 444-449.

Research output: Contribution to journalArticle

@article{fb12c0f4c89f48cbb9cfc281325ba56c,
title = "Processing of equine bone marrow using the automated MarrowXpress System: RBC depletion, volume reduction, and mononuclear cell recovery",
abstract = "Background: The therapeutic use of bone marrow-derived mononuclear cells (MNCs) and mesenchymal stem cells for the treatment of soft tissue and orthopedic injuries in equine patients is expanding. After collection, bone marrow must be reduced in volume and depleted of RBCs for immediate therapeutic use or to prepare cells for culture or cryopreservation and storage. The MarrowXpress (MXP) System is an automated, closed, sterile system designed to process human bone marrow samples. Objectives: The purpose of this study was to evaluate the capacity of the MXP System to process equine bone marrow to reduce volume, deplete RBCs, and enhance recovery of MNCs. Methods: Bone marrow was collected from 47 horses into 2 60-mL syringes containing heparin and processed using the MXP System. HCT, total nucleated cell (TNC) count, and MNC count were obtained for each sample before and after processing using an Advia 120 hematology analyzer. Volume reduction, RBC depletion, and recovery of TNCs and MNCs were calculated. Results: For equine bone marrow samples, mean values were 73.2{\%} for RBC depletion and 78.0{\%} for volume reduction. TNC count before processing was 2.5 ± 1.2 × 107 and after processing was significantly higher at 7.8 ± 3.3 × 107 (P < .0001), with a recovery of 68.5 ± 24.5{\%} (mean ± SD). MNC count before processing was 1.1 ± 0.9 × 107 and after processing was significantly higher at 3.8 ± 1.9 × 107 (P < .0001), with a recovery 73.0 ± 31.5{\%}. Conclusions: The MXP System can reliably reduce volume and deplete RBCs from aspirates of equine bone marrow aspirates. MNCs can be recovered in a reproducible and sterile manner. Further studies evaluating the effects of the MXP System on cell viability, identification of mesenchymal stem cells (MSCs), and the efficacy of MSC expansion are warranted.",
keywords = "Cartilage, Cell separation, Horse, Mesenchymal stem cells, Musculoskeletal, Tendon",
author = "Owens, {Sean D} and Julie Burges and Johns, {Jennifer L.} and Carrade, {Danielle D.} and Galuppo, {Larry D} and Fred Librach and Borjesson, {Dori L}",
year = "2011",
month = "12",
doi = "10.1111/j.1939-165X.2011.00368.x",
language = "English (US)",
volume = "40",
pages = "444--449",
journal = "Veterinary Clinical Pathology",
issn = "0275-6382",
publisher = "American Society for Veterinary Clinical Pathology",
number = "4",

}

TY - JOUR

T1 - Processing of equine bone marrow using the automated MarrowXpress System

T2 - RBC depletion, volume reduction, and mononuclear cell recovery

AU - Owens, Sean D

AU - Burges, Julie

AU - Johns, Jennifer L.

AU - Carrade, Danielle D.

AU - Galuppo, Larry D

AU - Librach, Fred

AU - Borjesson, Dori L

PY - 2011/12

Y1 - 2011/12

N2 - Background: The therapeutic use of bone marrow-derived mononuclear cells (MNCs) and mesenchymal stem cells for the treatment of soft tissue and orthopedic injuries in equine patients is expanding. After collection, bone marrow must be reduced in volume and depleted of RBCs for immediate therapeutic use or to prepare cells for culture or cryopreservation and storage. The MarrowXpress (MXP) System is an automated, closed, sterile system designed to process human bone marrow samples. Objectives: The purpose of this study was to evaluate the capacity of the MXP System to process equine bone marrow to reduce volume, deplete RBCs, and enhance recovery of MNCs. Methods: Bone marrow was collected from 47 horses into 2 60-mL syringes containing heparin and processed using the MXP System. HCT, total nucleated cell (TNC) count, and MNC count were obtained for each sample before and after processing using an Advia 120 hematology analyzer. Volume reduction, RBC depletion, and recovery of TNCs and MNCs were calculated. Results: For equine bone marrow samples, mean values were 73.2% for RBC depletion and 78.0% for volume reduction. TNC count before processing was 2.5 ± 1.2 × 107 and after processing was significantly higher at 7.8 ± 3.3 × 107 (P < .0001), with a recovery of 68.5 ± 24.5% (mean ± SD). MNC count before processing was 1.1 ± 0.9 × 107 and after processing was significantly higher at 3.8 ± 1.9 × 107 (P < .0001), with a recovery 73.0 ± 31.5%. Conclusions: The MXP System can reliably reduce volume and deplete RBCs from aspirates of equine bone marrow aspirates. MNCs can be recovered in a reproducible and sterile manner. Further studies evaluating the effects of the MXP System on cell viability, identification of mesenchymal stem cells (MSCs), and the efficacy of MSC expansion are warranted.

AB - Background: The therapeutic use of bone marrow-derived mononuclear cells (MNCs) and mesenchymal stem cells for the treatment of soft tissue and orthopedic injuries in equine patients is expanding. After collection, bone marrow must be reduced in volume and depleted of RBCs for immediate therapeutic use or to prepare cells for culture or cryopreservation and storage. The MarrowXpress (MXP) System is an automated, closed, sterile system designed to process human bone marrow samples. Objectives: The purpose of this study was to evaluate the capacity of the MXP System to process equine bone marrow to reduce volume, deplete RBCs, and enhance recovery of MNCs. Methods: Bone marrow was collected from 47 horses into 2 60-mL syringes containing heparin and processed using the MXP System. HCT, total nucleated cell (TNC) count, and MNC count were obtained for each sample before and after processing using an Advia 120 hematology analyzer. Volume reduction, RBC depletion, and recovery of TNCs and MNCs were calculated. Results: For equine bone marrow samples, mean values were 73.2% for RBC depletion and 78.0% for volume reduction. TNC count before processing was 2.5 ± 1.2 × 107 and after processing was significantly higher at 7.8 ± 3.3 × 107 (P < .0001), with a recovery of 68.5 ± 24.5% (mean ± SD). MNC count before processing was 1.1 ± 0.9 × 107 and after processing was significantly higher at 3.8 ± 1.9 × 107 (P < .0001), with a recovery 73.0 ± 31.5%. Conclusions: The MXP System can reliably reduce volume and deplete RBCs from aspirates of equine bone marrow aspirates. MNCs can be recovered in a reproducible and sterile manner. Further studies evaluating the effects of the MXP System on cell viability, identification of mesenchymal stem cells (MSCs), and the efficacy of MSC expansion are warranted.

KW - Cartilage

KW - Cell separation

KW - Horse

KW - Mesenchymal stem cells

KW - Musculoskeletal

KW - Tendon

UR - http://www.scopus.com/inward/record.url?scp=83055186523&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83055186523&partnerID=8YFLogxK

U2 - 10.1111/j.1939-165X.2011.00368.x

DO - 10.1111/j.1939-165X.2011.00368.x

M3 - Article

C2 - 22092275

AN - SCOPUS:83055186523

VL - 40

SP - 444

EP - 449

JO - Veterinary Clinical Pathology

JF - Veterinary Clinical Pathology

SN - 0275-6382

IS - 4

ER -